stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) Return on equity
Ionis Pharmaceuticals, Inc.'s return on equity over the twelve months to 30 June 2026 was −105.5%, down 34.7 percentage points from fiscal 2025 (−70.8%). Over the past ten years it has ranged from −93.1% (fiscal 2024) to 35.3% (fiscal 2018); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −70.8% | 22.30 |
| FY2024 | −93.1% | (16.76) |
| FY2023 | −76.3% | (36.22) |
| FY2022 | −40.1% | (36.34) |
| FY2021 | −3.78% | 32.82 |
| FY2020 | −36.6% | (55.97) |
| FY2019 | 19.4% | (15.90) |
| FY2018 | 35.3% | 35.12 |
| FY2017 | 0.15% | 40.37 |
| FY2016 | −40.2% | (1.72) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 5.38% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| ORKA Oruka Therapeutics, Inc. compare | −18.3% |
| CGON CG Oncology, Inc. compare | −26.4% |
| IMVT Immunovant, Inc. compare | −80.1% |
| IONS Ionis Pharmaceuticals, Inc. | −105.5% |
| AXSM Axsome Therapeutics, Inc. compare | −175.6% |
| KOD Kodiak Sciences Inc. compare | −368.4% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −760.0% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on IONS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement